Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Fahn

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Molecular Neurodegeneration|November 26, 2024
The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neuronsJace Jones-Tabah, Kathy He, Nathan Karpilovsky, et al.
Journal of the International Neuropsychological Society : JINS|November 25, 2010
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD StudyElise Caccappolo, Roy N Alcalay, Helen Mejia-Santana, et al.
Archives of Neurology|June 19, 2010
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease studyKaren S Marder, Ming X Tang, Helen Mejia-Santana, et al.
JAMA Neurology|November 6, 2013
Cognitive and motor function in long-duration PARKIN-associated Parkinson diseaseRoy N Alcalay, Elise Caccappolo, Helen Mejia-Santana, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 22, 2019
SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's diseaseRoy N Alcalay, Victoria Mallett, Benoît Vanderperre, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 19, 2013
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutationsRoy N Alcalay, Anat Mirelman, Rachel Saunders-Pullman, et al.
Archives of Neurology|July 21, 2004
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway, Ira Shoulson, Stanley Fahn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 31, 2021
Biallelic and monoallelic variants in PLXNA1 are implicated in a novel neurodevelopmental disorder with variable cerebral and eye anomaliesGabriel C Dworschak, Jaya Punetha, Jeshurun C Kalanithy, et al.
JAMA Neurology|November 17, 2015
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials, Kevin Michael Biglan, Ira Shoulson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 24, 2023
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD CohortEva-Juliane Vollstedt, Susen Schaake, Katja Lohmann, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Molecular Neurodegeneration|November 26, 2024
The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neuronsJace Jones-Tabah, Kathy He, Nathan Karpilovsky, et al.
Journal of the International Neuropsychological Society : JINS|November 25, 2010
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD StudyElise Caccappolo, Roy N Alcalay, Helen Mejia-Santana, et al.
Archives of Neurology|June 19, 2010
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease studyKaren S Marder, Ming X Tang, Helen Mejia-Santana, et al.
JAMA Neurology|November 6, 2013
Cognitive and motor function in long-duration PARKIN-associated Parkinson diseaseRoy N Alcalay, Elise Caccappolo, Helen Mejia-Santana, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 22, 2019
SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's diseaseRoy N Alcalay, Victoria Mallett, Benoît Vanderperre, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 19, 2013
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutationsRoy N Alcalay, Anat Mirelman, Rachel Saunders-Pullman, et al.
Archives of Neurology|July 21, 2004
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway, Ira Shoulson, Stanley Fahn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 31, 2021
Biallelic and monoallelic variants in PLXNA1 are implicated in a novel neurodevelopmental disorder with variable cerebral and eye anomaliesGabriel C Dworschak, Jaya Punetha, Jeshurun C Kalanithy, et al.
JAMA Neurology|November 17, 2015
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials, Kevin Michael Biglan, Ira Shoulson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 24, 2023
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD CohortEva-Juliane Vollstedt, Susen Schaake, Katja Lohmann, et al.
Pageof 17